Metagenomi Therapeutics

MGX · NASDAQ

$0.8313+$0.0195 (+2.40%)TodayMarket closed · Oct 20, 4:00 PM ET

Prev close $0.8118

MGX analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $7.14 (+758.9% upside)

Low: $5.05
Now: $0.8313
High: $9.45

Upgrades and downgrades

The latest rating actions, newest first

MGX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Aug 11, 2026	Maintains	Overweight	$9.00 → $7.00	32%
Chardan Capital	Jul 7, 2026	Maintains	Buy	$7.00 → $5.00	38%
Wells Fargo	May 12, 2026	Maintains	Overweight	$12.00 → $9.00	32%

The case for and against

Updated Feb 9, 2026

Bull case

Metagenomi Therapeutics Inc is focused on developing advanced genomic editing technologies aimed at creating curative treatments for various disorders, with a robust pipeline addressing conditions such as Hemophilia A and cardiovascular diseases. The company’s gene editing approach has demonstrated strong efficacy, achieving durable FVIII levels of 80% over a 19-month period in non-human primates, highlighting the potential for effective long-term treatment solutions. Furthermore, Metagenomi's dual strategy of advancing its pipeline while exploring technology out-licensing for ex vivo cell therapy positions it favorably within the expanding genetic therapeutics market.

Bear case

Metagenomi Therapeutics reported a substantial net loss of $19.9 million in its second quarter of 2025, equating to a loss of $0.54 per share. The company’s stock trades significantly below its cash value, suggesting potential for upside; however, this valuation is undercut by significant operational risks, including possible delays in clinical assessments and unfavorable clinical outcomes from trials for key candidates such as Hemophilia A and TTR. Additionally, there is an ongoing concern regarding potential long-term dilution, adding to the uncertainties surrounding the company's future financial performance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.